A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses.

Trial Profile

A Multicenter, Open-label Study of CMX001 Treatment of Serious Diseases or Conditions Caused by dsDNA Viruses.

Completed
Phase of Trial: Phase II/III

Latest Information Update: 07 Jan 2016

At a glance

  • Drugs Brincidofovir (Primary)
  • Indications DNA virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Chimerix
  • Most Recent Events

    • 08 Sep 2014 Results published in the Media Release.
    • 31 Jul 2014 Results in subset of renal transplant patients presented at the 2014 World Transplant Congress.
    • 31 Jul 2014 Results in subset of patients switching from cidofovir or foscarnet presented at the 2014 World Transplant Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top